Sociedad Americana de Hirudoterapia

Characterization of shed medicinal leech mucus reveals a diverse microbiota

Basic science published in Front Microbiol (2015)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenómica y proteómicaSeguridad y control de infeccionesOtt BM et al. · Frontiers in microbiology, 2015

Abstract

Microbial transmission through mucosal-mediated mechanisms is widespread throughout the animal kingdom. One example of this occurs with Hirudo verbana, the medicinal leech, where host attraction to shed conspecific mucus facilitates horizontal transmission of a predominant gut symbiont, the Gammaproteobacterium Aeromonas veronii. However, whether this mucus may harbor other bacteria has not been examined. Here, we characterize the microbiota of shed leech mucus through Illumina deep sequencing of the V3-V4 hypervariable region of the 16S rRNA gene. Additionally, Restriction Fragment Length Polymorphism (RFLP) typing with subsequent Sanger Sequencing of a 16S rRNA gene clone library provided qualitative confirmation of the microbial composition. Phylogenetic analyses of full-length 16S rRNA sequences were performed to examine microbial taxonomic distribution. Analyses using both technologies indicate the dominance of the Bacteroidetes and Proteobacteria phyla within the mucus microbiota. We determined the presence of other previously described leech symbionts, in addition to a number of putative novel leech-associated bacteria. A second predominant gut symbiont, the Rikenella-like bacteria, was also identified within mucus and exhibited similar population dynamics to A. veronii, suggesting persistence in syntrophy beyond the gut. Interestingly, the most abundant bacterial genus belonged to Pedobacter, which includes members capable of producing heparinase, an enzyme that degrades the anticoagulant, heparin. Additionally, bacteria associated with denitrification and sulfate cycling were observed, indicating an abundance of these anions within mucus, likely originating from the leech excretory system. A diverse microbiota harbored within shed mucus has significant potential implications for the evolution of microbiomes, including opportunities for gene transfer and utility in host capture of a diverse group of symbionts.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

Illumina 16S rRNA sequencing of shed H. verbana mucus reveals diverse microbiota dominated by Pedobacter (heparinase-producer), with Aeromonas and Rikenella-like bacteria conserved beyond gut.

Por qué esto importa para la hirudoterapia

This study characterized the microbiota of mucus shed by the medicinal leech Hirudo verbana using Illumina 16S rRNA V3-V4 sequencing, with RFLP/Sanger confirmation, and found dominance of Bacteroidetes and Proteobacteria, including Aeromonas veronii and Rikenella-like symbionts as well as putative novel leech-associated bacteria. It also reports that the most abundant genus, Pedobacter, includes members capable of producing heparinase, an enzyme that degrades the anticoagulant heparin. For ASH's domain, the work is relevant only as basic leech-associated microbiology because it concerns a medicinal leech species and a microbial activity connected to anticoagulant degradation; it does not describe the leech secretome or therapeutic effects. The abstract provides no clinical, pathogenicity, or hirudotherapy findings, so its relevance is indirect and limited to ecological/microbial context.

Citación

Characterization of shed medicinal leech mucus reveals a diverse microbiota.

Ott BM et al. · Frontiers in microbiology, 2015

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.